Brought to you by 
NeuroSearch AS spins off Acesion Pharma APS to focus on atrial fibrillation treatment, gets seed funding
02 Feb 2012
Executive Summary
NeuroSearch AS (CNS disorders) has spun off Acesion Pharma APS to focus on a cardiovascular program that had been discontinued under its NsDiscovery research division in September. Concurrent with the spin off, Acesion has brought in undisclosed seed funding from Novo Seeds and Seed Capital Denmark II/DTU Symbion Innovation AS.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeuroSearch AS spins off Acesion Pharma APS to focus on atrial fibrillation treatment, gets seed funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice